Search results
Showing 7951 to 8000 of 8140 results
NICE recommends 3 treatments for COVID-19 in final draft guidance
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments, under final draft guidance published by NICE today.
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.
NICE final draft guidance adds further treatment option for triple-negative breast cancer
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
Ground-breaking commercial deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit in final draft guidance published today (6 April 2023) by NICE that recommends it for some types of early breast cancer and advanced prostate cancer.
NICE gears up to support World Evidence-based Healthcare Day
Inaugural World Evidence-based Healthcare (EBHC) Day takes place on Tuesday 20 October 2020
NICE joins global alliance to shine spotlight on evidence-based healthcare
Tuesday 20 October will be the inaugural World Evidence-based Healthcare Day
NICE has joined a global group of organisations whose goal is to speed up the development and delivery of new, effective and affordable drugs to patients.
NICE joins international collaboratives to respond to the COVID-19 pandemic
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
NICE identifies improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
NICE is getting ready for the end of the transition period after Brexit
NICE has a key role in evaluation and access to new and innovative products for the health system, playing an important role in ensuring the UK remains a destination of choice for the life sciences sector.
NICE launches new Framework Agreement for purchasing information resources
NHS institutions can now purchase journals, books and databases to support patient care and safety at competitive rates, thanks to a new Framework Agreement launched by NICE.
NICE local formularies guide will 'reduce variation in prescribing'
NICE has produced a good practice guide to help trusts develop and update local formularies, as part of a move to ensure that all patients in England have access to clinically and cost-effective drugs.
NICE ME/CFS guideline outlines steps for better diagnosis and management
NICE has today (29 October 2021) published its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).
NICE non-executive director Elaine Inglesby-Burke CBE awarded Damehood for services to nursing
Elaine has been honoured in the Queen’s birthday honours list to recognise her commitment to the profession
NICE opens consultation on draft pelvic floor dysfunction guideline recommendations
NICE has today (28 June 2021) published its draft guideline on the prevention and non-surgical management of pelvic floor dysfunction and is seeking stakeholder comments on the draft recommendations.
NICE outlines steps needed to put ME/CFS guideline into practice
NICE has today, International ME Awareness Day (Thursday, 12 May 2022) published its implementation statement which sets out the practical steps needed to put its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) into
SIX health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.
NICE pauses publication of updated guideline on diagnosis and management of ME/CFS
NICE has today (17 August 2021) taken the decision to pause publication of its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).
NICE, PHE and SACN publish rapid COVID-19 guidance on vitamin D
NICE, PHE and SACN have today published rapid guidance on vitamin D for COVID-19.
NICE proposes simplifying how medicines and medical devices are selected for evaluation.
As part of the work underway to review the methods and processes NICE uses to develop guidance on medicines, medical devices and diagnostics, NICE has launched a public consultation on proposals for changing how it selects the topics it will develop guidance on.
NICE’s latest quality standard published today (16 March 2022) sets out how health and care services can improve the diagnosis, assessment, and prevention of fetal alcohol spectrum disorder (FASD).
NICE publishes final guideline advising on care throughout a woman's pregnancy
The updated antenatal care guideline focuses on women-centred care, informed shared decision making and the role of partners during pregnancy.
New guidelines cover the management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.
NICE publishes its first medtech briefing on artificial intelligence software
NICE publishes a Medtech Innovation Briefing on artificial intelligence for analysing CT brain scans
NICE publishes its guideline on the diagnosis and management of abdominal aortic aneurysms
NICE has today (19 March 2020) published its guideline on the diagnosis and management of abdominal aortic aneurysms (AAA).
NICE publishes latest COVID-19 guidance on renal transplantation
NICE has published new rapid COVID-19 guidance for children, young people and adults who need or who have had a kidney transplant, and people who are donating a kidney (live donors).
Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated into NICE’s new combined methods and processes manual and topic selection manual published today (31 January 2022).
The first is on the care of children and young people who are immunocompromised and the second on antibiotics for pneumonia in adults in hospital.
NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.
NICE has today (27 July 2020) published a guideline on the arrangements the NHS should put in place for patients needing elective surgery and other planned treatments and procedures (including diagnostics and imaging) during the COVID-19 pandemic.
NICE has today (29 July 2021) published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
NICE explores extending its use of data to inform its guidance
Consultation on proposal open until Friday 13 September
NICE extends consultation period for new quality standard on fetal alcohol spectrum disorder
NICE has today (20 August, 2020), released its draft quality standard on fetal alcohol spectrum disorder (FASD) for further public consultation.
Women should be offered the treatment option of their choice, in discussion with their clinician
NICE & SIGN announce latest rapid Covid-19 guideline will address Long Covid
NICE and the Scottish Intercollegiate Guidelines Network (SIGN) have today (5 October 2020) announced they will work with the Royal College of General Practitioners (RCGP) to develop a guideline on persistent effects of Covid-19 (Long Covid) on patients.
Research and knowledge sharing key to collaborative working approach agreed the two agencies
NICE seeks to support new mothers with mental health problems
NICE is calling on general practice staff to assess the mental health of all women who have recently given birth, as fears some may be left unsupported.
NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
NICE's methods of technology evaluation - presenting a case for change
NICE has today (6 November 2020) launched a public consultation on proposals for changes to the methods it uses to develop its guidance on medicines, medical devices and diagnostics.
NICE's new symptom–based approach will help to save thousands of lives from cancer
Thousands of lives in England could be saved each year if the NHS follows updated guidance to help it diagnose cancer earlier, NICE says.
NICE's processes of technology evaluation - presenting a case for change
NICE has today (4 February 2021) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.
NICE to become single point of access for Covid-19 guidance and advice
NICE has today (6 November) announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
NICE has today (20 March 2020) announced that it is developing a series of rapid guidelines with NHS England/Improvement on the active management of patients with suspected and confirmed COVID-19, and in patients without COVID-19, in a number of clinical areas.